Myeloproliferative disease Clinical Trials

9 recruitingLast updated: May 21, 2026

There are 9 actively recruiting myeloproliferative disease clinical trials across 7 countries. Studies span Phase 2. Top locations include Bologna, Italy, Torino, Italy, Bari, Italy. Updated daily from ClinicalTrials.gov.


Myeloproliferative disease Trials at a Glance

9 actively recruiting trials for myeloproliferative disease are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 2 trials, with the heaviest enrollment activity in Bologna, Torino, and Bari. Lead sponsors running myeloproliferative disease studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Fondazione Italiana Sindromi Mielodisplastiche-ETS, and Assistance Publique - Hôpitaux de Paris.

Browse myeloproliferative disease trials by phase

About Myeloproliferative disease Clinical Trials

Looking for clinical trials for Myeloproliferative disease? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myeloproliferative disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myeloproliferative disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting

Investigation of the Genetics of Hematologic Diseases

Diamond-Blackfan AnemiaDyskeratosis CongenitaFanconi Anemia+10 more
St. Jude Children's Research Hospital1,716 enrolled1 locationNCT02720679
Recruiting

Unveiling the Germline Predisposition to Myeloproliferative Neoplasms

Myeloproliferative diseaseGermline Mutation
Fondazione IRCCS Policlinico San Matteo di Pavia313 enrolled1 locationNCT07204392
Recruiting

Italian Network MDS Registry

Myelodysplastic-Myeloproliferative Diseases
Fondazione Italiana Sindromi Mielodisplastiche-ETS10,000 enrolled20 locationsNCT02808858
Recruiting

Myeloproliferative Neoplasms (MPNs) Patient Registry

NeoplasmsMastocytosisPolycythemia Vera+7 more
University Health Network, Toronto5,000 enrolled1 locationNCT02760238
Recruiting

The Patient Cohort of the National Center for Precision Medicine in Leukemia

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHigh Risk Myelodysplastic Syndrome+2 more
Assistance Publique - Hôpitaux de Paris3,000 enrolled3 locationsNCT05326919
Recruiting

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

Myeloproliferative diseaseInflammatory Markers
University of Milano Bicocca500 enrolled11 locationsNCT05553873
Recruiting
Phase 2

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

Myelodysplastic SyndromesAcute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% BlastsMixed Myelodysplastic/Myeloproliferative Disease
Karolinska University Hospital200 enrolled1 locationNCT05788679
Recruiting
Phase 2

A phase II study of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide as Graft versus Host Disease (GVHD) prophylaxis

Non Hodgkin's Disease in remissionAcute Myeloid Leukaemia in first or second complete remissionacute Lymphoblastic Leukaemia in first or second complete remission+7 more
St Vincent's Hospital Sydney70 enrolled6 locationsACTRN12617000151336